Loading
The tissue factor-directed antibody-drug conjugate tisotumab vedotin lengthened survival compared with chemotherapy in cervical cancer that had progressed after first-line treatment, at the cost of eye and nerve side effects.
Phase 3 trial of 502 patients with recurrent or metastatic cervical cancer after one or two prior systemic regimens randomised to tisotumab vedotin or investigator's choice chemotherapy (topotecan, vinorelbine, gemcitabine, irinotecan or pemetrexed).
Median overall survival was 11.5 versus 9.5 months (hazard ratio 0.70), progression-free survival 4.2 versus 2.9 months and objective response 17.8 versus 5.2 percent; ocular events, peripheral neuropathy and bleeding were the characteristic toxicities.
Tisotumab vedotin is the standard second-line treatment for recurrent cervical cancer after chemo-immunotherapy, with a mandatory eye-care protocol.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares Tisotumab vedotin, Recurrent or metastatic cervical cancer.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
Shares Tisotumab vedotin, Recurrent or metastatic cervical cancer.
Shares innovaTV 301 / ENGOT-cx12 / GOG-3057, Tisotumab vedotin.
Shares Recurrent or metastatic cervical cancer, New England Journal of Medicine.